Barrington raised the firm’s price target on HealthEquity (HQY) to $125 from $112 and keeps an Outperform rating on the shares. The company’s Q1 topped expectations and its fiscal 2026 guidance was raised, the analyst tells investors in a research note. The firm says that with a “strong and industry-leading” health savings account business, combined with a higher effective yield on cash, HealthEquity’s operating and financial performance should continue to improve on a consolidated basis going forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity price target raised to $115 from $98 at Deutsche Bank
- HealthEquity Inc. Earnings Call Highlights Growth and Legislative Wins
- HealthEquity price target raised to $125 from $100 at KeyBanc
- Morning Movers: Chart Industries, Flowserve both rise following merger pact
- HealthEquity price target raised to $117 from $112 at RBC Capital